Cargando…

Long acting β(2 )agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials

BACKGROUND: The long acting β2-agonists, salmeterol and formoterol, have been recommended, by some, as first line treatment of stable chronic obstructive pulmonary disease (COPD). We reviewed evidence of efficacy and safety when compared with placebo or anticholinergic agents in patients with poorly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Husereau, Don, Shukla, Vijay, Boucher, Michel, Mensinkai, Shaila, Dales, Robert
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC517721/ https://www.ncbi.nlm.nih.gov/pubmed/15339337 http://dx.doi.org/10.1186/1471-2466-4-7

Ejemplares similares

The safety of long-acting β(2)-agonists in the treatment of stable chronic obstructive pulmonary disease
por: Decramer, Marc L, et al.
Publicado: (2013)

The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease
por: Kliber, Agnes, et al.
Publicado: (2010)

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
por: Burkes, Robert M, et al.
Publicado: (2020)

The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
por: Tanimura, Kazuya, et al.
Publicado: (2023)

Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents
por: Tashkin, Donald P, et al.
Publicado: (2010)

Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
por: Rossi, Andrea, et al.
Publicado: (2008)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review
por: Ridolo, Erminia, et al.
Publicado: (2013)

Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial
por: Haney, Sarah, et al.
Publicado: (2005)

Reversible endotracheal tube obstruction caused by meconium acting as a check valve
por: Hwang, Wonjung, et al.
Publicado: (2014)

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
por: Liao, Pei-An, et al.
Publicado: (2023)

Comment on: “Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists”
por: Samuelsen, Carl, et al.
Publicado: (2015)

Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis
por: Donohue, James F, et al.
Publicado: (2017)

The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review
por: Zhou, Ji’an, et al.
Publicado: (2021)

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
por: Muraki, Masato, et al.
Publicado: (2021)

Efficacy and safety of the long-acting β(2)-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease
por: Ichinose, Masakazu, et al.
Publicado: (2015)

Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis
por: DiSantostefano, Rachael L, et al.
Publicado: (2014)

Economic evaluations of eHealth technologies: A systematic review
por: Sanyal, Chiranjeev, et al.
Publicado: (2018)

Paradoxical Bronchoconstriction with Short-Acting Beta Agonist
por: Magee, Jared S., et al.
Publicado: (2018)

Association of blood eosinophils and plasma periostin with FEV(1) response after 3-month inhaled corticosteroid and long-acting beta(2)-agonist treatment in stable COPD patients
por: Park, Hye Yun, et al.
Publicado: (2015)

Management of Asthma and Chronic Obstructive Pulmonary Disease with Combination Inhaled Corticosteroids and Long-Acting β-Agonists: A Review of Comparative Effectiveness Research
por: Mapel, Douglas W., et al.
Publicado: (2014)

Therapeutic preferences and factors determining the use of inhaled corticosteroids with long-acting β(2)-agonists in patients with asthma and chronic obstructive pulmonary disease
por: Olszanecka-Glinianowicz, Magdalena, et al.
Publicado: (2020)

Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists
por: Rebordosa, Cristina, et al.
Publicado: (2022)

Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting β2 Agonist: A Meta-analysis
por: Zeng, Shasha, et al.
Publicado: (2022)

Prescription of oral short-acting beta 2-agonist for asthma in non-resource poor settings: A national study in Malaysia
por: Chin, May Chien, et al.
Publicado: (2017)

Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data
por: Husereau, Don, et al.
Publicado: (2018)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Evaluating Stable Chronic Obstructive Pulmonary Disease by Ultrasound
por: Evrin, Togay, et al.
Publicado: (2019)

Pharmacological therapy for stable chronic obstructive pulmonary disease
por: Duan, Ruirui, et al.
Publicado: (2023)

Long-Acting Reversible Contraception
por: Machado, Rogerio Bonassi, et al.
Publicado: (2017)

Eosinophil values in exacerbation and stable chronic obstructive pulmonary disease and its relationship to maintenance therapy in stable chronic obstructive pulmonary disease patients
por: Fachri, Muhammad, et al.
Publicado: (2023)

Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study
por: Horita, Nobuyuki, et al.
Publicado: (2013)

Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long‐Acting β (2)‐Agonists and Inhaled Corticosteroids: The OUTPUL Study
por: Ferroni, Eliana, et al.
Publicado: (2016)

Passive Monitoring of Short-Acting Beta-Agonist Use via Digital Platform in Patients With Chronic Obstructive Pulmonary Disease: Quality Improvement Retrospective Analysis
por: Chen, Jessica, et al.
Publicado: (2019)

The long-acting β(2)-adrenoceptor agonist olodaterol attenuates pulmonary inflammation
por: Wex, Eva, et al.
Publicado: (2015)

Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England
por: Requena, Gema, et al.
Publicado: (2022)

The Insurance Act and Poor-Law Infirmaries
por: Parsons, C. Thackray
Publicado: (1913)

The Insurance Act and Poor-Law Infirmaries
Publicado: (1912)

Biobleaching application of cellulase poor and alkali stable xylanase from Bacillus pumilus SV-85S
por: Nagar, Sushil, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7glpkjlrujrfven8k0nn9u284p